El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Biotechnology Surging
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
PHARMA JONPI .: 08/24/14
Puma Biotechnology
Puma Biotechnology
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
La EMA recomienda no aprobar el fármaco de Puma Biotech
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma – PHARMA
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Pharma (@PumaPharma) / Twitter
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Men – PHARMA
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma – PHARMA
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
